Blueprint, Deciphera present Phase I GIST data

Blueprint Medicines Corp. (NASDAQ:BPMC) and Deciphera Pharmaceuticals LLC (Waltham, Mass.) each presented Phase I data Thursday for candidates targeting stem cell factor (SCF) receptor tyrosine kinase (c-KIT; KIT; CD117) and platelet

Read the full 312 word article

User Sign In